Work

206TiP SIERRA: A phase IIIb, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma

Year: 2023

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2023.10.785

Authors: S.L. Chan, B. Sangro, M. Kudo, A. Dane, C. Emery, M. Paskow, M. Makowsky, B. Nguyen, L. Rimassa

Institutions: Chinese University of Hong Kong, Clinica Universidad de Navarra, Kindai University Hospital, Kindai University, AstraZeneca (United Kingdom), AstraZeneca (United States), Humanitas University, IRCCS Humanitas Research Hospital

Language: English

Topic: Hepatocellular Carcinoma Treatment and Prognosis

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4389280710

FWCI: 1.133

Cites:

Cited by: 8

Related to: 10